Payment overview · 2025
General Payments
$1,323.04
69 reported records · 21 companies
Healthcare provider profile · identity verified
Stephen C Young, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MIDLOTHIAN, VA · NPI 1609849637
Verified facts
What the public records show
CMS Open Payments records show Stephen C Young, M.D. received $1,323.04 in general payments during 2025 across 69 reported records.
Novo Nordisk Inc accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Unithroid.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UNITHROID as an associated drug or biological on 7282 records involving 3230 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Unithroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $375.41 | 28.4% | 23 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $154.09 | 11.7% | 11 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $108.13 | 8.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $104.44 | 7.9% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $83.64 | 6.3% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $67.62 | 5.1% | 4 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $64.80 | 4.9% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.94 | 3.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.77 | 3.2% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $38.94 | 2.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.17 | 2.6% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $31.35 | 2.4% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $25.16 | 1.9% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $23.08 | 1.7% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $22.12 | 1.7% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.76 | 1.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.21 | 1.4% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $16.68 | 1.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.24 | 1.1% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.17 | 1.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.32 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,323.04 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $248.38 | 15 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $178.39 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $127.03 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $115.72 | 9 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $108.13 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $104.44 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $83.64 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $68.95 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $67.62 | 4 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $64.80 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.77 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $41.77 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $38.94 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.17 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $31.35 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 242 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 255 | exact normalized | Medicare Part D |
| UNITHROID unithroid |
2025 | Unithroid | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | UNITHROID open payments reported associated product |
CMS Open Payments — General Payments 7282 supporting records · 3230 recipient NPIs · example record 1220525525 |
Unithroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
242 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
242 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
255 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
42 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 893 | 236 |
| Levothyroxine Sodium | Levothyroxine Sodium | 660 | 165 |
| Atorvastatin Calcium | Atorvastatin Calcium | 560 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 501 | 142 |
| Lisinopril | Lisinopril | 394 | 106 |
| Carvedilol | Carvedilol | 341 | 92 |
| Losartan Potassium | Losartan Potassium | 311 | 88 |
| Metformin Hcl Er | Metformin Hcl | 272 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 270 | 72 |
| Valsartan | Valsartan | 264 | 69 |
| Omeprazole | Omeprazole | 259 | 70 |
| Ozempic | Semaglutide | 255 | 50 |
| Jardiance | Empagliflozin | 242 | 52 |
| Glimepiride | Glimepiride | 232 | 68 |
| Gabapentin | Gabapentin | 220 | 56 |
| Trazodone Hcl | Trazodone Hcl | 211 | 61 |
| Montelukast Sodium | Montelukast Sodium | 205 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 199 | 50 |
| Ezetimibe | Ezetimibe | 195 | 55 |
| Meloxicam | Meloxicam | 191 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 173 | 51 |
| Synthroid | Levothyroxine Sodium | 169 | 45 |
| Simvastatin | Simvastatin | 164 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 50 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 141 | 45 |
| Metformin Hcl | Metformin Hcl | 125 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 32 |
| Alprazolam | Alprazolam | 115 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 32 |
| Allopurinol | Allopurinol | 109 | 30 |
| Cephalexin | Cephalexin | 107 | 70 |
| Bupropion Xl | Bupropion Hcl | 98 | 28 |
| Sertraline Hcl | Sertraline Hcl | 98 | 33 |
| Farxiga | Dapagliflozin Propanediol | 97 | 22 |
| Tramadol Hcl | Tramadol Hcl | 97 | 17 |
| Azithromycin | Azithromycin | 92 | 81 |
| Humalog Kwikpen U-100 | Insulin Lispro | 89 | 30 |
| Novolog Flexpen | Insulin Aspart | 76 | 23 |
| Famotidine | Famotidine | 74 | 27 |
| Ramipril | Ramipril | 72 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 41 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 20 |
| Potassium Chloride | Potassium Chloride | 70 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 20 |
| Spironolactone | Spironolactone | 68 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 18 |
| Celecoxib | Celecoxib | 63 | 13 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 63 | 16 |
| Eliquis | Apixaban | 62 | 15 |
| Irbesartan | Irbesartan | 62 | 16 |
| Diazepam | Diazepam | 60 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 14 |
| Atenolol | Atenolol | 56 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 22 |
| Januvia | Sitagliptin Phosphate | 56 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 56 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 17 |
| Methylprednisolone | Methylprednisolone | 52 | 45 |
| Furosemide | Furosemide | 50 | 24 |
| Mounjaro | Tirzepatide | 50 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 18 |
| Eszopiclone | Eszopiclone | 48 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 48 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 47 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 20 |
| Pregabalin | Pregabalin | 45 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 28 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Lorazepam | Lorazepam | 42 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 11 |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 40 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | 15 |
| Finasteride | Finasteride | 38 | suppressed |
| Acyclovir | Acyclovir | 37 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | 14 |
| Humalog Kwikpen U-200 | Insulin Lispro | 36 | 12 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 31 | 24 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Testosterone | Testosterone | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Repaglinide | Repaglinide | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 23 | suppressed |
| Unithroid | Levothyroxine Sodium | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Levoxyl | Levothyroxine Sodium | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Prednisone | Prednisone | 16 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Linzess | Linaclotide | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Codeine Sulfate | Codeine Sulfate | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Saxagliptin-Metformin Er | Saxagliptin Hcl/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,323.04 · 69 records | Novo Nordisk Inc | AFREZZA, AREXVY, CeQur Simplicity, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GVOKE HYPOPEN, INTELLIS ADAPTIVESTIM, JARDIANCE, JATENZO, LEQVIO, MOUNJARO, NURTEC ODT, Omnipod, Ozempic, PROLIA, RECORLEV, REZDIFFRA, Rybelsus, SHINGRIX, TEPEZZA, TWIIST, UNITHROID, VYKAT XR, Wegovy, Yorvipath, ZAVZPRET, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amneal Pharmaceuticals LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error